Company: CERO
Filing Date: 2025-01-07
Form Type: 424B3
Source: 0001213900-25-001657
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-07
Form: 424B3
Chunk 7
---
 projections, forecasts or forward-looking
statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, the Company’s
management.

Actual results could differ
from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ include,
among others: outcomes of the Company’s planned clinical trials and studies may not be favorable; that one or more of the Company’s
product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results
from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products;
uncertainties regarding intellection property protection; and those set forth in the Company’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The
risks described in the Company’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge
from time to time, and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors
on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those
contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance
on these statements, which speak only as of the date hereof. All forward-looking statements made by the Company or persons acting on its
behalf are expressly qualified in their entirety by the foregoing cautionary statements. The Company undertakes no obligation to update
or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. 
 3.1         
 99.1        |     | Description                                                                                                                  
 Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of CERo Therapeutics Holdings, Inc. 
 Press release, dated January 6, 2025.                                                                                        |
|:------------|:----|:-----------------------------------------------------------------------------------------------------------------------------|
| 104         |     | Cover Page Interactive Data File (Embedded within the Inline XBRL Document).                                                 |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of